Skip to main content
Retour
AVNS logo

Avanos Medical, Inc.

Qualité des données : 100%
AVNS
NYSE Healthcare Medical - Devices
13,40 €
▲ 0,36 € (2,72%)
Cap. Boursière : 623,15M
Fourchette du Jour
13,25 € 13,57 €
Fourchette 52 Semaines
9,30 € 15,68 €
Volume
555 712
Moyenne 50J / 200J
13,60 € / 12,15 €
Clôture Précédente
13,05 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -9,2 0,4
P/B 0,8 2,9
ROE % -8,5 3,7
Net Margin % -9,7 3,8
Rev Growth 5Y % -1,5 10,0
D/E 0,2 0,2

Points Clés

Revenue declined -1,49% annually over 5 years
Debt/Equity of 0,17 — conservative balance sheet
Generating 43,10M in free cash flow
PEG of 0,09 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,44%
Capital efficient — spends only 4,51% of revenue on capex

Croissance

Revenue Growth (5Y)
-1,49%
Revenue (1Y)1,95%
Earnings (1Y)N/A
FCF Growth (3Y)71,82%

Qualité

Return on Equity
-8,45%
ROIC-5,09%
Net Margin-9,68%
Op. Margin-8,78%

Sécurité

Debt / Equity
0,17
Current Ratio2,15
Interest Coverage-15,40

Valorisation

P/E Ratio
-9,18
P/B Ratio0,80
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 1,95% Revenue Growth (3Y) 2,05%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -1,49% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 701,20M Net Income (TTM) -67,90M
ROE -8,45% ROA -6,32%
Gross Margin 49,77% Operating Margin -8,78%
Net Margin -9,68% Free Cash Flow (TTM) 43,10M
ROIC -5,09% FCF Growth (3Y) 71,82%
Safety
Debt / Equity 0,17 Current Ratio 2,15
Interest Coverage -15,40 Dividend Yield 0,00%
Valuation
P/E Ratio -9,18 P/B Ratio 0,80
P/S Ratio 0,89 PEG Ratio 0,09
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 623,15M Enterprise Value 662,45M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 701,20M 687,80M 673,30M 684,10M 744,60M
Net Income -67,90M -392,10M -61,80M 50,50M 6,30M
EPS (Diluted) -1,46 -8,53 -1,33 1,07 0,13
Gross Profit 349,00M 381,30M 379,70M 394,20M 379,90M
Operating Income -61,60M 40,00M 65,00M 41,90M 86,80M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,07B 1,15B 1,69B 1,79B 1,60B
Total Liabilities 295,50M 325,70M 456,10M 495,70M 333,00M
Shareholders' Equity 778,20M 828,50M 1,24B 1,29B 1,27B
Total Debt 129,10M 170,20M 209,10M 277,00M 187,50M
Cash & Equivalents 89,80M 107,70M 87,70M 127,70M 118,50M
Current Assets 355,40M 393,40M 487,00M 624,10M 427,60M
Current Liabilities 165,20M 165,90M 234,60M 191,00M 139,20M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#503 of 820
36

Activité Récente

Entré Deep Value Investing (Seth Klarman)
Mar 24, 2026